Hester Biosciences Ltd
Hester Biosciences Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage. Management is confident about sustaining and improving growth, particularly in the Poultry Healthcare division.
From Hester Biosciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage.
- Post Q3 FY26, regulatory approval of the H9N2 Avian Influenza vaccine positions the company well for both domestic and export growth.
- Expansion of manufacturing capacity through capitalized fill/finish facility will support scale-up of existing products and introduction of new products.
- Animal Healthcare division is expected to gain momentum in Q4 FY26 with the commencement of government immunization programs (PPR and Goat Pox) after prior delays.
- Focus on reducing dependency on tender-based revenues by increasing direct sales to commercial and export markets.
- Long-term growth underpinned by ongoing innovation, technological depth, and strategic initiatives to leverage capacity and market opportunities.
- EBITDA and profitability are expected to improve year-on-year, reflecting operational discipline and better product mix management.
Profitability & Margins
See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has capitalized a fill/finish facility, effectively doubling drug product capacity.
- Remaining capital work in progress (CWIP) worth INR 182 crores is expected to be capitalized over the coming months.
- Capex is structured in phases to support scale-up across products and markets, with progressive returns as utilization increases.
- No current plans for contract manufacturing or innovator-led manufacturing; focus remains on retaining brand and exporting directly.
- The BSL-3 facility originally for COVID vaccine production is being evaluated for repurposing into an animal vaccine manufacturing facility; specifics are yet to be finalized.
- Petcare segment expansion is underway without incremental capex, leveraging existing facilities for potential vaccine opportunities.
- Overall strategic focus on capacity strengthening, reducing tender dependence, and supporting future growth through measured capex investment.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- No specific details or figures about the current or expected order book or pending orders were disclosed in the transcript.
- The management discussed ongoing efforts to reduce dependence on tender-based revenues and increase direct sales in both domestic and export markets.
- Institutional orders, especially in Africa, are subject to timing delays linked to government-led immunization program funding releases and rollout schedules.
- The company reported that the delay in immunization programs (like PPR and goat pox vaccines) affected Animal Health segment revenues but is expected to resume from February 2026 with improved momentum.
- Overall, the focus remains on steady execution, capacity strengthening, and building a more balanced and resilient business, implying a stable order flow aligned with these strategies.
Hester Biosciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Hester Biosciences Ltd Q3 FY26 results?
The company aims to sustain and grow its Poultry Healthcare business, supported by deeper market penetration, improved placement, and stronger distribution coverage. Management is confident about sustaining and improving growth, particularly in the Poultry Healthcare division.
What is Hester Biosciences Ltd share price analysis?
Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.7 with a market cap of ₹2,054 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Biosciences Ltd planning capital expenditure?
The company has capitalized a fill/finish facility, effectively doubling drug product capacity.
Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.